[go: up one dir, main page]

WO2010019263A3 - Soluble flt constructs for treating cancers - Google Patents

Soluble flt constructs for treating cancers Download PDF

Info

Publication number
WO2010019263A3
WO2010019263A3 PCT/US2009/004665 US2009004665W WO2010019263A3 WO 2010019263 A3 WO2010019263 A3 WO 2010019263A3 US 2009004665 W US2009004665 W US 2009004665W WO 2010019263 A3 WO2010019263 A3 WO 2010019263A3
Authority
WO
WIPO (PCT)
Prior art keywords
constructs
treating cancers
soluble flt
fusion proteins
flt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/004665
Other languages
French (fr)
Other versions
WO2010019263A2 (en
Inventor
Rebecca Bagley
Johanne Kaplan
Beverly Teicher
Jim Stefano
Clark Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of WO2010019263A2 publication Critical patent/WO2010019263A2/en
Publication of WO2010019263A3 publication Critical patent/WO2010019263A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Multimeric fusion proteins of an Ig-like domain of Flt-1 linked to a multimerization domain, either directly or using a linker moiety, are useful for treating certain tumors and pathological neovascularization. The fusion proteins can be produced recombinantly and readily purified using a simple two-column procedure. The columns employ a hydrophobic charge induction resin and a ceramic hydroxyapatite resin.
PCT/US2009/004665 2008-08-15 2009-08-14 Soluble flt constructs for treating cancers Ceased WO2010019263A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8931108P 2008-08-15 2008-08-15
US61/089,311 2008-08-15
US9250508P 2008-08-28 2008-08-28
US61/092,505 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010019263A2 WO2010019263A2 (en) 2010-02-18
WO2010019263A3 true WO2010019263A3 (en) 2010-08-12

Family

ID=41669536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/004665 Ceased WO2010019263A2 (en) 2008-08-15 2009-08-14 Soluble flt constructs for treating cancers

Country Status (2)

Country Link
AR (1) AR073078A1 (en)
WO (1) WO2010019263A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2229956E (en) 2004-09-13 2013-07-31 Genzyme Corp Multimeric constructs
PT2601214T (en) * 2010-08-06 2017-12-20 Genzyme Corp Vegf antagonist compositions and uses thereof
JP6254146B2 (en) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Compositions and methods for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
RU2703145C2 (en) 2014-02-06 2019-10-15 Джензим Корпорейшн Compositions and methods of treating and preventing macular degeneration
MY192917A (en) 2014-07-30 2022-09-15 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
CN113166271A (en) * 2018-05-18 2021-07-23 郑州晟斯生物科技有限公司 Fusion Polypeptide Conjugates with Extended Half-Life
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
KR20250114439A (en) * 2019-07-23 2025-07-29 론지튜드 테라퓨틱스 에스.알.엘. Platelet-facilitated delivery of therapeutic compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017977A1 (en) * 1999-06-08 2003-01-23 Yuping Xia Methods of treating inflammatory skin diseases
US20040198957A1 (en) * 2001-08-27 2004-10-07 Inna Way Method for removing endotoxins from protein solutions
US20060115876A1 (en) * 2004-11-12 2006-06-01 Bayer Healthcare Llc Site-directed modification of FVIII
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017977A1 (en) * 1999-06-08 2003-01-23 Yuping Xia Methods of treating inflammatory skin diseases
US20040198957A1 (en) * 2001-08-27 2004-10-07 Inna Way Method for removing endotoxins from protein solutions
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs
US20060115876A1 (en) * 2004-11-12 2006-06-01 Bayer Healthcare Llc Site-directed modification of FVIII

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISCHER ET AL.: "Anti-PIGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels.", CELL, vol. 131, 2 November 2007 (2007-11-02), pages 463 - 475 *
GAGNON ET AL.: "A Ceramic Hydroxyapatite? Based Purification Platform Simultaneous Removal of Leached Protein A, Aggregates, DNA, and Endotoxins from MAbs.", BIOPROCESS INTERNATIONAL., February 2006 (2006-02-01), pages 50 - 56, Retrieved from the Internet <URL:www.validated.com/revalbio/pdffiles/bpicht.pdf> [retrieved on 20100524] *

Also Published As

Publication number Publication date
WO2010019263A2 (en) 2010-02-18
AR073078A1 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
WO2010019263A3 (en) Soluble flt constructs for treating cancers
MX2012000765A (en) Improved anti-serum albumin binding single variable domains.
WO2011036564A3 (en) Hyperblebbing shigella strains
MX2022008904A (en) SYNTHESIS OF GAMMA-FUSIONED CARBOLINES WITH SUBSTITUTED HETEROCYCLE.
MX2011008752A (en) Improved anti-serum albumin binding variants.
WO2010027827A3 (en) Targeted costimulatory polypeptides and methods of use to treat cancer
EP3144322A3 (en) Bispecific binding molecules binding to vegf and ang2
WO2010118169A3 (en) Human protein scaffold with controlled serum pharmacokinetics
WO2009055343A3 (en) Fully human anti-vegf antibodies and methods of using
WO2010003766A3 (en) Multimeric tnf receptors
AU2010310545A8 (en) Anti-GCC antibody molecules and related compositions and methods
AU2012328921A8 (en) Immunobinders directed against TNF
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
PH12012501991A1 (en) Tnf-alpha binding proteins
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
MX2022013520A (en) Cxcr2 binding polypeptides.
MX2013002379A (en) Vegf-binding molecules.
WO2010020766A3 (en) Interleukin fusion polypeptides
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
EP3656788A3 (en) Improved anti-serum albumin binding variants
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
WO2011031477A3 (en) Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
WO2011112566A3 (en) Basigin binding proteins
MX2013011032A (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09806983

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09806983

Country of ref document: EP

Kind code of ref document: A2